Brainstorm Cell (NASDAQ: BCLI)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.130 | -0.150 | -0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Brainstorm Cell (NASDAQ: BCLI) through any online brokerage.
Other companies in Brainstorm Cell’s space includes: Anixa Biosciences (NASDAQ:ANIX), Fortress Biotech (NASDAQ:FBIO), OncoCyte (NASDAQ:OCX), Ambrx Biopharma (NYSE:AMAM) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Brainstorm Cell (NASDAQ: BCLI) was reported by Maxim Group on Friday, February 5, 2021. The analyst firm set a price target for 0.00 expecting BCLI to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
The stock price for Brainstorm Cell (NASDAQ: BCLI) is $2.78 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Brainstorm Cell.
Brainstorm Cell’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Brainstorm Cell.
Brainstorm Cell is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.